P0560Sarcopenia and Clinical Outcomes in Inflammatory Bowel Disease: A Prospective Monocentric Study

Abstract Background Sarcopenia, reflecting loss of skeletal muscle mass and strength, is increasingly recognized in IBD and may influence disease course and outcomes. Aim To determine the prevalence of sarcopenia and its impact on 6-month adverse outcomes in IBD patients. Methods This prospective monocentric study was conducted at Mohammed VI University Hospital, Marrakech (January 2024 – June 2025). Ninety-eight patients were included (Crohn’s disease = 56; ulcerative colitis = 42). Sarcopenia was assessed according to EWGSOP2 criteria: handgrip strength, appendicular skeletal muscle index (ASMI via bioimpedance), gait speed, and SARC-F score. Nutritional parameters (BMI, albumin, prealbumin, MNA-SF/NRS-2002) and inflammatory biomarkers (CRP, fecal calprotectin) were recorded. The primary endpoint was a composite event at 6 months (relapse, hospitalization, surgery, or therapeutic escalation). Statistical analysis included univariate comparisons and multivariate Cox regression. Results Mean age was 39.7 ± 12.2 years; 54 % were female; mean BMI = 23.5 ± 4.2 kg/m². Sarcopenia prevalence was 34.7 %. Sarcopenic patients had lower BMI (22.2 ± 3.9 vs 24.4 ± 3.6; p = 0.012), lower albumin (34.8 ± 4.2 vs 39.6 ± 5.0 g/L; p 0.001), and higher CRP (17.3 ± 11.8 vs 11.2 ± 8.9 mg/L; p = 0.019). Overall, 41 patients (41.8 %) experienced a composite event, more frequent among sarcopenic subjects (58.8 % vs 32.3 %; p = 0.009). In multivariate Cox analysis, sarcopenia remained an independent predictor of adverse outcome (HR = 2.45, 95 % CI 1.21–4.96; p = 0.012) after adjustment for age, sex, BMI, disease activity, and biologic therapy. Conclusion Sarcopenia affects over one-third of IBD patients and independently doubles the risk of adverse outcomes. Systematic screening for sarcopenia should be integrated into nutritional and prognostic assessment to guide individualized patient management. References: Conflict of interest: Dr. Aouroud, Hala: No conflict of interest Aouroud, Meryem: No conflict of interest Nacir, Oussama: No conflict of interest lairani, fatima ezzahra: No conflict of interest ait errami, adil: No conflict of interest Oubaha, Sofia: No conflict of interest Samlani, Zouhour: No conflict of interest Krati, Khadija: No conflict of interest